NCT04859777 - A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions

Solid Tumor, AdultAdvanced Solid TumorAdvanced CancerMetastatic CancerRefractory Cancer

Interventions

DRUG

MPT-0118

MPT-0118 is an inhibitor of MALT1 protease

DRUG

MPT-0118 + pembrolizumab

MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor

Trial Locations (5)

RECRUITING

Columbia University, New York

RECRUITING

MD Anderson Cancer Center, Houston

RECRUITING

NEXT Oncology, San Antonio

RECRUITING

St. John's Cancer Center, Santa Monica

RECRUITING

Massachusetts General Hospital, Boston